Development Of Non-surgical Approach To Treating Tricuspid Regurgitation
Funder
National Health and Medical Research Council
Funding Amount
$266,427.00
Summary
Heart failure is a common problem in which the heart enlarges and contracts poorly. In association with enlargement of the heart, the heart valves also begin to fail causing further worsening of quality and length of life. Failure of the tricuspid valve occurs in upto 87% of patients with heart failure and presently the only treatment option is high risk heart surgery. We are developing a way of dealing with tricuspid valve failure that does not require cardiac surgery.
Heart-lung Interactions Determine Right Ventricular Function In The Perinatal Period.
Funder
National Health and Medical Research Council
Funding Amount
$421,980.00
Summary
Birth, and the ensuing stress of newborn life, requires the heart to dramatically increase its level of functioning. Understanding how this process occurs remains a key problem as the heart lacks any ability to increase its level of functioning immediately before birth. Failure to effect this increase in heart function promptly at birth has serious implications for the well being of the newborn and represents a major problem in newborn medicine. Of the 250,000 babies born each year in Australia, ....Birth, and the ensuing stress of newborn life, requires the heart to dramatically increase its level of functioning. Understanding how this process occurs remains a key problem as the heart lacks any ability to increase its level of functioning immediately before birth. Failure to effect this increase in heart function promptly at birth has serious implications for the well being of the newborn and represents a major problem in newborn medicine. Of the 250,000 babies born each year in Australia, as many as 5,000 require intensive care primarily for cardiorespiratory complications. Accurate diagnosis and effective treatment of these infants demands knowledge of the normal heart adaptations that accompany birth, adaptations that are critically linked to the way in which the heart and the lungs interact. This project investigates how interactions between the heart and the lungs determines heart function throughout life. By understanding this process we will provide essential information that will aid the diagnosis and treatment of sick neonates undergoing intensive care.Read moreRead less
Benefit Of 2D-strain Surveillance In Improving Cardiovascular Outcomes In Cancer Patients Undergoing Cardiotoxic Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$2,391,979.00
Summary
Cancer survivors are susceptible to heart failure (HF) caused by heart muscle damage from chemotherapy. The current testing for this problem is based on a measure that cannot identify minor changes of cardiac function. Cardiac strain is a sensitive new marker of cardiac function which is predictive of overt dysfunction & HF. This study seeks to identify whether strain can be used to assign treatments that lead to improved cardiac function and are eventually associated with a reduction in HF.
I am a cardiology research scientist investigating the differences between physiological (“good”) and pathological (“bad”) heart growth- cardiac hypertrophy. In general, heart failure research and therapy has concentrated on identifying and inhibiting pathological processes. In contrast, my research is unique because it has focused on activating physiological pathways (elevated in the athlete’s heart) in the failing heart as a potential new strategy for the treatment of heart failure and atrial ....I am a cardiology research scientist investigating the differences between physiological (“good”) and pathological (“bad”) heart growth- cardiac hypertrophy. In general, heart failure research and therapy has concentrated on identifying and inhibiting pathological processes. In contrast, my research is unique because it has focused on activating physiological pathways (elevated in the athlete’s heart) in the failing heart as a potential new strategy for the treatment of heart failure and atrial fibrillation.Read moreRead less
NOVEL CGMP-BASED THERAPIES PREVENT LEFT VENTRICULAR REMODELLING
Funder
National Health and Medical Research Council
Funding Amount
$533,433.00
Summary
Over 300,000 Australians are affected by heart failure. Current drugs for cardiac remodelling (the decline in heart pumping function and changed structure that precede heart failure) slow but not reverse disease progression. We have identified a new, nitrovasodilator-based therapy superior to those currently available. We propose it represents a more effective treatment for reversing abnormalities in both structure and function in the remodelled heart, preventing or delaying heart failure.
TARGETING ROS-INDUCED DAMAGE RESCUES THE DIABETIC HEART
Funder
National Health and Medical Research Council
Funding Amount
$487,669.00
Summary
Over 1 million Australians have diabetes. Many of these patients die from cardiovascular disease. We have identified free radicals as a major cause of decreased pumping function and impaired recovery from each heartbeat in the diabetic heart. Stronger antioxidant approaches and-or activation of protective protein pathways is a more effective treatment for reversing impaired function in the diabetic heart, preventing or delaying heart failure in patients with diabetes.
Screening Evaluation Of The Evolution Of New Heart Failure Extension Study
Funder
National Health and Medical Research Council
Funding Amount
$849,992.00
Summary
Heart failure is a major burden on patients with this condition and on the community. The SCReening Evaluation of the Evolution of New Heart Failure (SCREEN-HF) study is evaluating the use of a blood test to identify individuals with undiagnosed heart failure and abnormal heart function, and those at increased risk of these conditions, so that more people can benefit from currently available therapies for the treatment and prevention of heart failure.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
Funder
National Health and Medical Research Council
Funding Amount
$815,185.00
Summary
Diabetes affects almost 2 million Australians, creating an increasing heart failure burden. A/Prof Rebecca Ritchie’s team at Baker IDI are interested in the precise role of cardiac inflammation in the progression of cardiomyopathy resulting from diabetes. Using her exciting discovery that a naturally-occurring anti-inflammatory protein is a key regulator of cardiac muscle cell survival and function, A/Prof Ritchie’s team will develop therapies for diabetic cardiomyopathy based on this protein.